Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients with Type 2 Diabetes Treated with Metformin Alone or in Combination with Sulphonylurea

Trial Profile

Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients with Type 2 Diabetes Treated with Metformin Alone or in Combination with Sulphonylurea

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2018

At a glance

  • Drugs Exenatide (Primary) ; Insulin detemir
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Amylin Pharmaceuticals; AstraZeneca
  • Most Recent Events

    • 01 Apr 2018 Results of pooled post hoc analysis of this and other ten trials assessing the relationship of heart rate changes with baseline heart rate and identifying patient characteristics associated with changes in heart rate in the Exenatide QW development program published in the Diabetes Therapy
    • 10 Jun 2017 Biomarkers information updated
    • 18 Sep 2014 Results of a pooled analysis of trials NCT00641056, NCT01003184, and NCT00935532 were presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top